How Does CAR-T Therapy's Efficacy Translate to Clinical Value for Hong Kong Patients with Refractory Hematological Malignancies, and How Can Optimized Manufacturing Help Close the Current Access Gap?
DOI:
https://doi.org/10.71222/dt007s28Keywords:
car-t immunotherapy, hematological malignancies, cell therapy manufacturing, healthcare accessibility, clinical translation, treatment optimization, Hong Kong healthcareAbstract
This comprehensive review examines the transformative potential of Chimeric Antigen Receptor (CAR)-T cell therapy in treating refractory hematological malignancies, with specific focus on its clinical implementation in Hong Kong SAR, China. CAR-T therapy represents a revolutionary advancement in blood cancer treatment, offering a potentially curative single-treatment option for patients who have exhausted standard therapeutic approaches. Global data demonstrates remarkable success, with documented durable remissions among over 40,000 treated patients worldwide. However, the translation of these benefits to Hong Kong's healthcare landscape faces significant challenges. The study analyzes critical manufacturing bottlenecks, extended wait times, and limited treatment slot availability that currently restrict patient access in Hong Kong SAR, China. Our research highlights promising technological improvements, specifically an EF1α-driven CD19 CAR construct achieving 59.9% transduction efficiency, exceeding typical clinical benchmarks of 30-70%. Through detailed statistical modeling, we demonstrate the potential for a seven-day reduction in manufacturing timeline, resulting in a 42% increase in treatment throughput. This optimization could significantly reduce patient attrition and potentially save 30-40 additional lives annually in Hong Kong SAR, China. The analysis encompasses manufacturing optimization strategies, regulatory considerations, and healthcare system integration requirements to enhance CAR-T therapy accessibility while maintaining therapeutic efficacy.References
1. C. Johnston, B. Martin, G. Fichant, P. Polard, and J. P. Claverys, "Bacterial transformation: distribution, shared mechanisms and divergent control," Nature Reviews Microbiology, vol. 12, no. 3, pp. 181-196, 2014.
2. R. K. Ngan, "Overview of Hong Kong, China cancer statistics of 2015," Lung, vol. 4, no. 135, p. 1, 2017.
3. E. R. Pennings et al., "Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe," Blood Advances, vol. 9, no. 24, pp. 6380-6393, 2025.
4. F. Bray et al., "Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: a cancer journal for clinicians, vol. 74, no. 3, pp. 229-263, 2024.
5. D. Andreu-Sanz et al., "Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis," Journal for ImmunoTherapy of Cancer, vol. 13, no. 6, e011698, 2025.
6. S. T. Bhaskar, B. Dholaria, B. N. Savani, S. Sengsayadeth, and O. Oluwole, "Overview of approved CAR-T products and utility in clinical practice," Clinical Hematology International, vol. 6, no. 4, p. 93, 2024.
7. H. Metzger, "The effect of antigen on antibodies: recent studies," Contemporary Topics in Molecular Immunology, pp. 119-152, 1978.
8. A. J. Chen, J. Zhang, A. Agarwal, and D. N. Lakdawalla, "Value of reducing wait times for chimeric antigen receptor T-cell treatment: evidence from randomized controlled trial data on tisagenlecleucel for diffuse large B-cell lymphoma," Value in Health, vol. 25, no. 8, pp. 1344-1351, 2022.
9. B. E. Freund et al., "Acute symptomatic seizures during CAR T-cell therapy for hematologic malignancies: tri-site Mayo Clinic experience," Neurology, vol. 104, no. 9, e213535, 2025.
10. L. Dan and K.-Z. L., "Optimizing viral transduction in immune cell therapy manufacturing: key process design considerations," Journal of Translational Medicine, vol. 23, no. 1, p. 501, 2025.
11. E. Mok, "Hong Kong, China healthcare system and its challenges," JONA: The Journal of Nursing Administration, vol. 31, no. 11, pp. 520-523, 2001.
12. K. Fujiwara et al., "Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold," Cells, vol. 9, no. 5, p. 1182, 2020.
13. N. Ahmed et al., "“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy," Frontiers in Oncology, vol. 13, 1206715, 2023.
14. S. Naik et al., "International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML," Blood Advances, vol. 9, no. 23, pp. 6047-6058, 2025.
15. Y. Liu and Z. Zheng, "Understanding the global cancer statistics 2022: growing cancer burden," Science China. Life Sciences, vol. 67, no. 10, pp. 2274-2276, 2024.
16. K. M. McKinnon, "Flow cytometry: an overview," Current Protocols in Immunology, vol. 120, no. 1, p. 5-1, 2018.
17. Y. J. Chen, B. Abila, and Y. Mostafa Kamel, "CAR-T: what is next?," Cancers, vol. 15, no. 3, p. 663, 2023.
18. A. Froger and J. E. Hall, "Transformation of plasmid DNA into E. coli using the heat shock method," Journal of Visualized Experiments: JoVE, no. 6, p. 253, 2007.
19. K. M. Cappell and J. N. Kochenderfer, "Long-term outcomes following CAR T cell therapy: what we know so far," Nature Reviews Clinical Oncology, vol. 20, no. 6, pp. 359-371, 2023.
20. H. Owji et al., "A comprehensive review of signal peptides: Structure, roles, and applications," European Journal of Cell Biology, vol. 97, no. 6, pp. 422-441, 2018.
21. A. Mullard, "In vivo CAR T cells move into clinical trials," Nat Rev Drug Discov, vol. 23, no. 10, pp. 727-730, 2024.
22. U. K. Myeloma, "What is myeloma," Retrieved September, 1, 2017.
23. P. C. Johnson et al., "Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy," Blood Advances, vol. 7, no. 14, pp. 3541-3550, 2023.
24. Y. H. Cheng et al., "The Filterprep: A simple and efficient approach for high-yield, high-purity plasmid DNA purification," New Biotechnology, 2025.
25. D. M. Safley et al., "Comparison of costs between transradial and transfemoral percutaneous coronary intervention: a cohort analysis from the Premier research database," American Heart Journal, vol. 165, no. 3, pp. 303-309, 2013.
26. X. Rios et al., "Refining chimeric antigen receptors via barcoded protein domain combination pooled screening," Molecular Therapy, vol. 31, no. 11, pp. 3210-3224, 2023.
27. W. A. Lim and C. H. June, "The principles of engineering immune cells to treat cancer," Cell, vol. 168, no. 4, pp. 724-740, 2017.
28. A. Carbone et al., "High efficiency method to obtain supercoiled DNA with a commercial plasmid purification kit," Acta Biochimica Polonica, vol. 59, no. 2, pp. 275-278, 2012.
29. H. M. Bizuayehu et al., "Global disparities of cancer and its projected burden in 2050," JAMA Network Open, vol. 7, no. 11, e2443198, 2024.
30. L. H. Sehn et al., "Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data," Blood Advances, vol. 6, no. 2, pp. 533-543, 2022.
31. S. Busby and R. H. Ebright, "Promoter structure, promoter recognition, and transcription activation in prokaryotes," Cell, vol. 79, no. 5, pp. 743-746, 1994.
32. N. J. Nonzee et al., "Delays in cancer care among low-income minorities despite access," Journal of Women's Health, vol. 24, no. 6, pp. 506-514, 2015.
33. J. Seigner et al., "Solving the mystery of the FMC63-CD19 affinity," Scientific Reports, vol. 13, no. 1, p. 23024, 2023.
34. S. Tully et al., "Impact of increasing wait times on overall mortality of chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a discrete event simulation model," JCO Clinical Cancer Informatics, vol. 3, pp. 1-9, 2019.
35. M. A. Ashfaq et al., "Post-transcriptional gene silencing: Basic concepts and applications: MA Ashfaq et al.," Journal of Biosciences, vol. 45, no. 1, p. 128, 2020.
36. M. Winiarska et al., "Selection of an optimal promoter for gene transfer in normal B cells," Molecular Medicine Reports, vol. 16, no. 3, pp. 3041-3048, 2017.
37. X. Wang, D. Niu, C. Hu, and P. Li, "Polyethyleneimine-based nanocarriers for gene delivery," Current Pharmaceutical Design, vol. 21, no. 42, pp. 6140-6156, 2015.
38. V. Wittibschlager et al., "CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma," International Journal of Molecular Sciences, vol. 24, no. 6, p. 5688, 2023.
39. L. Wang et al., "Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells," Cytotherapy, vol. 21, no. 5, pp. 566-578, 2019.
40. C. Teschendorf, K. H. Warrington Jr, D. W. Siemann, and N. Muzyczka, "Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus," Anticancer Research, vol. 22, no. 6A, pp. 3325-3330, 2002.
